Generic drug makers are hailing the planned creation of a new government fund designed to support the industry’s manufacturing infrastructure,…
BUSINESS
New Grad Hiring Down 3.3% at 55 Drug Makers, Sales Rep Opportunities Fall amid DX: Survey
Fifty-five drug makers in Japan decreased their new grad hiring this spring by 3.3% versus last year, a Jiho survey revealed, with more than half of respondent companies shedding this number. Jiho sent out an annual employment survey sheet to…
To read the full story
Related Article
BUSINESS
- Bain Strikes Deal to Buy Mitsubishi Tanabe
February 7, 2025
- UCB Bags Japan Approval for Bimzelx’s 320 mg Auto-Injector
February 7, 2025
- AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies
February 7, 2025
- Kura/Kyowa Kirin’s AML Drug Inches Closer to FDA Filing on Positive PII Data
February 7, 2025
- Kyowa Kirin’s Profit Sags on R&D Spending, but Overseas Biz Fares Well
February 7, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…